Long-Term Cardiomyopathy Risk Varies by Chemo Agent
FRIDAY, March 1, 2019 -- Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.
Elizabeth A.M....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Cardiomyopathy | Chemotherapy | Childhood Cancer | Heart | Pharmaceuticals | Study